Sensex Today | Macquarie keeps ‘neutral’ rating on Dr Reddy’s Laboratories, target price at Rs 1,190
#1 Q2 EBITDA miss on in-line revenue
#2 Ozempic (Semaglutide): Management expects Health Canada response, CRL risk not ruled out
#3 Biosimilar: Company’s initial biosimilar submission (Rituximab) to US FDA has resulted in a CRL
#4 Management confident on abatacept (IV) filing by December 2025 of Bachupally facility
Dr Reddys Laboratories was quoting at Rs 1,287.25, up Rs 3.25, or 0.25 percent.
It has touched an intraday high of Rs 1,289.90 and an intraday low of Rs 1,265.00.
It was trading with volumes of 31,262 shares, compared to its five day average of 76,756 shares, a decrease of -59.27 percent.
In the previous trading session, the share closed up 0.32 percent or Rs 4.15 at Rs 1,284.00.
The share touched a 52-week high of Rs 1,404.60 and a 52-week low of Rs 1,025.90 on 08 January, 2025 and 07 April, 2025, respectively.
Currently, the stock is trading 8.35 percent below its 52-week high and 25.48 percent above its 52-week low.
Market capitalisation stands at Rs 107,435.66 crore.